Aspirin Dosing Considerations In Essential Thrombocythemia: The ARES Trial

Aspirin Dosing Considerations In Essential Thrombocythemia: The ARES Trial Overview In patients diagnosed with essential thrombocythemia (ET), the standard treatment involves once-daily low-dose aspirin to mitigate the risk of thrombosis. However, due to accelerated platelet turnover in these patients, the antiplatelet effect of aspirin diminishes over time. A study called the Short-term

Chemotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma

Chemotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma Overview This study aimed to investigate serious chemotherapy-induced thrombocytopenia (CIT) in nasopharyngeal carcinoma (NPC), focusing on its incidence, consequences, and predictors. The retrospective analysis of NPC patients from 2013 to 2015 revealed a 5.21% incidence of serious chemotherapy-induced thrombocytopenia. Patients experiencing severe thrombocytopenia had notably worse long-term prognoses,

Aspirin Dosing Considerations In Essential Thrombocythemia: The ARES Trial